Skip to main content
Fig. 3 | Molecular Medicine

Fig. 3

From: Anti-tuberculosis chemotherapy alters TNFR2 expression on CD4+ lymphocytes in both drug-sensitive and -resistant tuberculosis: however, only drug-resistant tuberculosis maintains a pro-inflammatory profile after a long time

Fig. 3

Frequency of actCD4+ tmTNF+ and actCD4+ TNFR2+ T cells decrease in response to anti-TB therapy in DR-TB. Peripheral mononuclear cells from drug-susceptible (DS-TB) and drug-resistance (DR-TB) tuberculosis patients were obtained at diagnosis time (basal), 2 months (2 m), and 6 months (6 m) of use of anti-TB therapy, and then they were prepared for flow cytometry. For analysis, a gate of CD3+ CD4+ CD25+ Foxp3− cells (activated CD4+ T cells, actCD4+) was identified. Then, the expression of tmTNF, tmTNFR1 and tmTNFR2 on actCD4+ cell surface was evaluated. A The frequency of actCD4+ cells was obtained at basal, 2 m and 6 m of anti-TB therapy. Frequency of actCD4+ cells positive to tmTNF (B), tmTNFR1 (C) and tmTNFR2 (D) were evaluated. DS-TB n = 11, DR-TB n = 7. Bar graphs showing the mean ± SD. One Way ANOVA with Dunn's post-test multiple comparisons tests (*p < 0.05)

Back to article page

Molecular Medicine

ISSN: 1528-3658